Dr. Matthew Barrett, an expert in Parkinson disease, and Dr. Michael S. Okun, a prominent researcher in biomarkers, delve into the intricacies of biological staging in Parkinson disease. They discuss the ongoing need for caution when redefining classifications, emphasizing the importance of alpha-synuclein biomarkers. The duo highlights challenges in personalized staging and the complexities of diagnosis, while advocating for adaptive systems that can evolve alongside research. Their conversation underlines the necessity for inclusive dialogue and equitable access in advancing care.
